PI(3,4)P\(_2\) plays critical roles in the regulation of focal adhesion dynamics of MDA-MB-231 breast cancer cells

Miki Fukumoto, Takeshi Ijuin and Tadaomi Takenawa

Key words
Cell invasion, focal adhesion, Lpd, PI(3,4)P\(_2\), SHIP2

Correspondence
Takeshi Ijuin, Division of Biochemistry, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki, Chu-o, Kobe, 650-0017, Japan.
Tel: +81-78-382-5429; Fax: +81-78-382-5439;
E-mail: tijuin@med.kobe-u.ac.jp

Funding Information
This work was supported by grants to T. I. from the Japan Society for the Promotion of Science (JSPS; Kakenhi grant number 16K08585).

Received October 20, 2016; Revised February 17, 2017; Accepted February 22, 2017

Cancer Sci | 108 (2017) 941–951
doi: 10.1111/cas.13215

Breast cancer metastasis is one of the major causes of cancer-related mortality in women worldwide. Metastasis is a multistep process: after cell spreading, cancer cells form lamellipodia and migrate through the assembly of branched F-actin networks. This cytoskeletal rearrangement is mediated by actin-regulatory proteins including Rac1, WAVEs, and Mena/Ena/VASP proteins. Mena is frequently upregulated in breast cancer cells and promotes cell migration. Lamellipodin (Lpd), also referred to as Raph1, localizes to lamellipodia and recruits Mena/Ena/VASP to membrane protrusions. Lpd was shown to regulate random motility in breast cancer cells and is required for lamellipodia formation.

PI3-kinase (PI3K) signaling has critical roles in cell proliferation, survival, and motility. PI3K\(_P2\), generated from PI(4,5)P\(_2\) through PI3K activity, is an important secondary messenger involved in the activation of Akt. A high proportion of breast cancer cells acquire the ability to activate and sustain PI3K/Akt signaling, which contributes to therapeutic resistance. More than 70% of breast cancers have alterations in at least one component of the PI3K/Akt pathway, including PIK3CA, PTEN, and Akt. Among them, PIK3CA, the gene that encodes the catalytic subunit of Class I PI3K, is mutated and activated in breast cancers. These mutations, most frequently observed in estrogen and/or progesterone receptor-positive and HER2-positive breast tumors, but rarely identified in triple-negative tumors, lead to the activation of PI3K/Akt signaling, resulting in the initiation of breast cancer. PTEN, a tumor suppressor that hydrolyzes PI(3,4)P\(_2\) to PI(3,5)P\(_2\) suppresses PI3K/Akt signaling. Although PTEN mutations are less frequent, loss of heterozygosity at the PTEN locus frequently occurs in breast cancer. PI(3,4)P\(_2\) loss is observed in 30–40% of sporadic cases of breast cancer that are associated with hyperactivation of PI3K/Akt signaling, and results in the accumulation of PI(3,5)P\(_2\) and tumor progression. In addition, the phosphoinositide 4-phosphatase, INPP4B, which hydrolyzes PI(3,4)P\(_2\) to PI(3)P, inhibits PI3K/Akt signaling, and was identified as a tumor suppressor in breast cancer. In 84% of basal-like breast cancers, loss of INPP4B expression occurs and INPP4B loss-of-heterogeneity frequently occurs in BRCA1-mutant and triple-negative basal-like breast cancers. INPP4B knockdown was shown to induce Akt activation and anchorage-independent growth. In addition, loss of heterogeneity at the INPP4B locus was found in the majority of estrogen receptor-negative basal-like breast cancers.

Recent studies identified that a number of phosphoinositide 5-phosphatases that hydrolyze PI(3,4,5)P\(_3\) serve as PTEN signal terminators. The expression of SKIP (also referred to as INPP5K) can be altered in brain cancers. In PTEN-null glioblastoma cells, SKIP overexpression inhibits cell migration through regulation of the actin cytoskeleton. PIPP (INPP5J) is frequently inactivated in triple-negative breast cancers, and functions as a tumor suppressor. Its inactivation promotes...
tumor growth and suppresses metastasis. The SH2 domain-containing inositol 5-phosphatase SHIP2, also referred to as INPP5L1, which dephosphorylates PIP3 and PI(4,5)P2 to generate PI(3,4)P2 and PI(4)P2 respectively, has a negative effect on PI3K/Akt signaling. SHIP2 knockout mice show mild insulin hypersensitivity and resistance to high fat diet-induced obesity. This protein is overexpressed in human breast cancers, and correlates with shorter survival. SHIP2 localizes to the focal contacts and lamellipodia and inhibits cell migration in PTEN-null 1321 N1 glioblastoma cells through de-phosphorylation of PI(4,5)P2. In contrast, a number of studies have suggested that SHIP2 is often amplified in human cancer cells, whereas the tumor suppressors PTEN and INPP4B are often mutated or deleted, which leads to sustained activation of PIP3-dependent Akt signaling in these cells. However, it is not clear how amplification of SHIP2 is involved in the malignancy of cancer cells, though this event is expected to lead to decreased PIP3 levels.

Increasing evidence suggests that PI(3,4)P2, which is generated from PIP3, not only induces the activation of Akt, but can act independently to regulate processes such as membrane ruffle formation, podosome formation, lamellipodia formation, and lamellipodia maturation. Recent studies showed that PIP(3,4)P2 depletion impairs motility during B cell chemotaxis, and that Lpd, whose PH domain specifically binds to PI(3,4)P2, co-localizes with PI(3,4)P2 to mediate directional migration. Thus, PI(3,4)P2 is an important signaling molecule that is involved in regulating cytoskeletal rearrangements and the plasma membrane. Other studies have demonstrated the role of Lpd in the actin cytoskeletal network. Lpd and Ena/VASP were found to interact with the WAVE regulatory complex and membrane-bound Lpd directly binds to filamentous actin and recruits Ena/VASP, and WAVE activities the lamellipodial actin network.

Focal adhesions (FAs) are macromolecular assemblies that sense extracellular stimuli and signaling complexes that play central roles in cell migration. Upon mechanical tension, some grow into larger and stable FAs and recruit various proteins including zyxin (ZYX) through a process known as FA maturation to modulate integrin signaling for cell migration. Lpd and several focal adhesion proteins, including focal adhesion kinase (FAK), the adapter proteins p130Cas (Cas), and paxillin (PAX), play a role in transducing ECM stiffness into intracellular stiffness. The information encoded by ECM stiffness is transduced into intracellular stiffness by integrins, the transmembrane adhesion receptors for ECM proteins, focal adhesion proteins, and the actin cytoskeleton. Vinculin, a focal adhesion protein that binds to PI(4,5)P2, has been implicated in the stiffness-sensing event. However, it is still unclear whether PI(3,4)P2 and its effector protein Lpd regulate focal adhesion dynamics and migration in breast cancer cells.

We hypothesized that PI(3,4)P2 has a pivotal role in focal adhesion dynamics and lamellipodia formation, leading to increased motility and invasion in cancer cells. In this study, we examined the effect of SHIP2 and/or PTEN knockdown on the dynamic regulation of focal adhesion formation and the invasion of PTEN-positive and INPP4B-null MDA-MB-231 basal breast cancer cells, and found that knockdown of SHIP2 decreased PI(3,4)P2 levels, which in turn induced the development of FA and the suppression of invasion. Our results indicate that the PI(3,4)P2-Lpd signaling pathway, controls focal adhesion dynamics in breast cancer cells.

Materials and methods

Reagents and antibodies. The anti-phospho-FAK (Tyr-397) antibody (Catalog No. 44-624G) was purchased from Life Technologies (Carlsbad, CA, USA). Anti-FAK antibody (Catalog No. 610087) was purchased from BD Transduction Laboratories (San Jose, CA, USA). Anti-pan Akt (Catalog No. 5804) and anti-phospho-Akt (Ser-473, Catalog No. 4060) antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). The anti-zyxin (ZYX) (Catalog No. HPA004835) and anti-vinculin (VCL) (Catalog No. V9131) antibodies were purchased from Sigma-Aldrich (St. Louis, MO, USA). The anti-SHIP2 (Catalog No. 2839) and anti-phospho-paxillin (PAX) (Tyr-118, Catalog No. 2541) antibodies were purchased from Cell Signaling Technology. The anti-paxillin antibody (Catalog No. 610051) was from BD Biosciences (San Jose, CA, USA). The anti-actin antibody (Catalog No. MAB1501) was purchased from EMD Millipore (Billerica, MA, USA). LY294002 and wortmannin were purchased from Merck Millipore (Darmstadt, Germany).

Cell culture. The human breast cancer MDA-MB-231 cell line was purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Wako, Osaka, Japan) supplemented with 10% fetal bovine serum (FBS), 4 mM L-glutamine, streptomycin, and penicillin.

Plasmids and transfection. Full-length human SHIP2 cDNA were obtained by reverse transcription (RT)-polymerase chain reaction (PCR) using total RNA isolated from MDA-MB-231 cells as a template. cDNA was cloned into pEGFP-C1 vector (Takara bio, Otsu, Japan). Furthermore, cDNA encoding TAPP1 PH, FAP1 PH, PLCγ1 PH, and Grp1 PH were isolated as described previously.

RNA interference (RNAi). The following stealth siRNA species (Life Technologies) targeting human SHIP2, PTEN, and Lpd were used for RNAi experiments. The targeted sequences of the Stealth siRNA species used in this study are as follows: control, Stealth RNAi siRNA negative control med GC (Catalog No. 12935-300), SHIP2 #1, 5′-CAGGAGAUCGUCAAGAUCAUCAGCA-3′, SHIP2 #2, 5′-GAGGUUGAGGUUACCCUCAGAUCUA-3′, PTEN, 5′-CCAUGCCUAAGAAGGATC GCAAU-3′, Lpd #1, 5′-CCACGGCUAGAUCAUGCUGUAUUAU-3′, and Lpd #2, 5′-GCAAUGUAGGGACACGCUUAUC-3′. siRNA was transfected into MDA-MB-231 cells using Lipofectamine RNAiMAX reagent (Life Technologies) according to the manufacturer’s protocol.

Immunofluorescence microscopy. Cells were transfected with plasmids or siRNA for 24–48 h and then re-plated on fibronectin (FN)-coated coverslips. Cells were cultured for 24 h, and then fixed with 4% paraformaldehyde for 10 min at room temperature, which was followed by permeabilization with phosphate-buffered saline (PBS) containing 0.2% Triton X-100 for 5 min. Coverslips were washed twice with PBS and then incubated with primary antibody for 1 h at room temperature. Alexa Fluor 568-conjugated anti-rabbit IgG or anti-mouse antibodies (Life Technologies) were used as secondary antibodies. The coverslips were mounted with PermaFluor Aqueous Mounting Medium (Thermo Scientific, Waltham, MA, USA) and analyzed using a FluoView 1000-D confocal microscope (Olympus, Tokyo, Japan).

Western blotting. MDA-MB-231 cells cultured in FN-coated dishes were lysed with Laemmli sample buffer, briefly sonicated, and boiled at 95°C for 5 min. Western blotting was performed by standard procedures with detection using alkaline
phosphatase-conjugated secondary antibodies (Promega, Madison, WI, USA).

**Quantification of focal adhesions and cell area.** The number of focal adhesions was calculated as follows. Cells were immunostained with anti-PAX or anti-VCL antibody. The number of PAX- or VCL-positive plaques per cell was counted using ImageJ software (National Institute of Health, Bethesda, MD, USA). Eighty cells were analyzed for each experiment. For the quantification of cell area, cells were immunostained with rhodamine- or Alexa Fluor 647-conjugated phalloidin and were imaged by confocal microscopy. Eighty cells were used to quantify cell area.

**Matrigel invasion assay.** The invasion assay was performed as previously described. MDA-MB-231 cells were seeded in the upper compartment of a BD Biocoat Matrigel Invasion Chamber (BD Biosciences) and incubated with DMEM containing 10% FBS in the lower well and serum-deprived medium in the top chamber. After 22 h, the cells were fixed with 3.7% formaldehyde in PBS for 30 min. Cells were washed with PBS and cells on the undersurface of the filter were observed by confocal microscopy.

**Statistical analysis.** For multiple comparisons, P-values were generated by one-way analysis of variance using the Student-Newman-Keuls multiple comparison tests. For two group analysis, P-values were calculated by Student’s t-test.

**Quantification of phosphoinositides.** Plasma membrane phosphoinositides were quantified as follows. To measure PI(3,4)P₂, PI(4,5)P₂, and PIP₃ levels, the laser intensity of EGFP-TAPP1 PH, -PLC<div class="onecol" style="float: right; width: 300px; height: 300px;" align="right"><img src="https://www.wileyonlinelibrary.com/journal/cas"/></div>d₁ PH, and –GRP1 PH, respectively, were analyzed using the Trainable Weka Segmentation plugin with Image J software.

**Results**

**SHIP2 knockdown increases the number of focal adhesions and cell area.** Focal adhesions that connect the actin cytoskeleton with the extracellular matrix and focal adhesion-associated proteins such as Akt, FAK, and PAX, regulate cell invasion, metastasis, and migration.⁴⁴⁻⁴⁷ These proteins are localized to focal adhesions and are phosphorylated upon focal adhesion development.⁴⁷⁻⁴⁹ We examined the effect of SHIP2 silencing in MDA-MB-231 breast cancer cells on the expression and activation of Akt, FAK, and PAX. SHIP2 knockdown increased the phosphorylation of PAX at Tyr-118, which is involved in mature focal adhesion formation (Fig. 1a), without affecting phosphorylation of FAK at Tyr-397, and Akt at Ser-473. Since Akt phosphorylation is dependent on PIP₃, these results imply that SHIP2 knockdown increases PIP₃ levels by a very small amount. Next, the effect of SHIP2 knockdown on focal adhesion formation was examined. MDA-MB-231 cells exhibited an elongated shape with polarized membranes, reflecting a highly invasive phenotype. The number of VCL- and ZYX-positive focal adhesions increased after SHIP2 knockdown (Fig. 1b,c). In these cells, stress fibers formed and the cell area also increased (Fig. 1b,d).

**SHIP2 alters PIP(3,4)P₂ at focal contacts.** To examine whether SHIP2 hydrolyzes PIP₃ at focal contacts, GFP-SHIP2 was expressed in MDA-MB-231 cells. This protein was localized...
Fig. 2. Effect of SHIP2 knockdown on PIP₃ and PI(3,4)P₂ levels at the focal adhesions. (a) GFP-SHIP2-expressing MDA-MB-231 cells were stained with a VCL antibody. Enlarged images of the boxed areas are indicated in the lower panels. The arrows indicate membrane ruffles. Scale bar = 10 μm. (b) MDA-MB-231 cells transfected with control (siCTL) or SHIP2 #1 (siSHIP2) siRNA were stained with VCL. For the detection of PIP₃ and PI(3,4)P₂, GFP-GRP1-PH or GFP-TAPP1 PH was also expressed in these cells. F-actin was visualized with Alexa Fluor 647 labeled-phalloidin. Enlarged images of boxed areas are indicated in the lower panels. The arrows and arrowheads indicate focal adhesions and membrane ruffles, respectively. Scale bar = 10 μm. (c) MDA-MB-231 cells transfected with Control (siCTL) or SHIP2 #1 (siSHIP2) siRNA were stained with VCL. To detect PI(4,5)P₂ and PI(4)P, GFP-PLCδ1-PH or GFP-FAPP1 PH was also expressed in these cells. F-actin was visualized with Alexa Fluor 647 labeled-phalloidin. Enlarged images of boxed areas are indicated in the lower panels. The arrows and arrowheads indicate focal adhesions and membrane ruffles, respectively. Scale bar = 10 μm.

© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
to the lamellipodia and VCL-positive focal contacts (Fig. 2a). Since focal contacts and lamellipodia are formed during the initial stages of cell spreading before the development of focal adhesions, these results imply a role of SHIP2 in the assembly and/or disassembly of focal contacts. Next, the localization of PIP3 and PI(3,4)P2 were observed using GFP-GRP1 PH and GFP-PLCγ1 PH, which specifically bind to PIP3 and PI(3,4)P2, respectively. (50) PIP3 was predominantly localized to the lamellipodia and focal contacts at the front of cells in both control- and SHIP2 siRNA-transfected cells (Fig. 2b). In addition, PI(3,4)P2 was localized to the lamellipodia and partially to VCL-positive focal contacts. In SHIP2 knockdown cells, VCL-positive focal contacts were observed and PI(3,4)P2 localization was no longer observed (Fig. 2b). Because SHIP2 also controls PI(4,5)P2 and PI(4)P at the plasma membrane in 1321 N1 glioblastoma cells, (30) the effect of SHIP2 knockdown on these phosphoinositides at the plasma membrane was examined. Representative images of GFP-FAPP1 PH and GFP-PLCγ1 PH, which bind to PI(4)P and PI(4,5)P2, are shown. Localization of these phosphoinositides at the PM was not changed by SHIP2 depletion in MDA-MB-231 cells (Fig. 2c).

To examine the effect of PIP3 generation on focal adhesion formation, MDA-MB-231 cells were treated with PI3-kinase inhibitors including wortmannin and LY294002. These inhibitors completely inhibited PIP3-dependent Akt phosphorylation, showing complete abolishment of PIP3 generation. Representative images of GFP-FAPP1 PH and GFP-TAPP1 PH, which specifically bind to PI(3,4)P2 and PI(4,5)P2 at the plasma membrane in 1321 N1 glioblastoma cells, (30) the effect of SHIP2 knockdown on these phosphoinositides at the plasma membrane was examined. Representative images of GFP-FAPP1 PH and GFP-PLCγ1 PH, which bind to PI(4)P and PI(4,5)P2, are shown. Localization of these phosphoinositides at the PM was not changed by SHIP2 depletion in MDA-MB-231 cells (Fig. 2c).

To examine the effect of PIP3 generation on focal adhesion formation, MDA-MB-231 cells were treated with PI3-kinase inhibitors including wortmannin and LY294002. These compounds completely inhibited PI3-kinase-dependent Akt phosphorylation, showing complete abolishment of PIP3 generation (Fig. 3a). These inhibitors increased PAX phosphorylation (Fig. 3a) and increased focal adhesions number and cell areas (Fig. 3b–d). To clarify whether PI(3,4)P2 contributes to these changes, the effect of PI3-kinase inhibitors on relative amount of PI(3,4)P2 and PI(4,5)P2 levels at the PM were examined. Fluorescence intensity of EGFP-TAPP1 PH domain that binds to PI(3,4)P2 has been measured to quantify PI(3,4)P2 levels at the plasma membrane. We found that PM PI(3,4)P2 levels were decreased, whereas the fluorescence intensity of EGFP-PLCγ1 PH that binds to PI(4,5)P2 was not altered by these inhibitors (Fig. 3e,f). These results suggest that the generation of PI(3,4)P2 by SHIP2 promotes the formation of lamellipodia and suppresses the development of focal adhesions, whereas PI3 and PI(4,5)P2 are unlikely to play any role in these processes.

**Differential effect of PTEN and SHIP2 knockdown on focal adhesion development and cell invasion.** PTEN is a 3-phosphatase of PIP3 and PI(3,4)P2, which catalyzes the production of PI(3,4)P2 and PI(4)P, respectively. We compared the effect of SHIP2 and PTEN knockdown on focal adhesions in MDA-MB-231 cells. SHIP2 knockdown did not alter Akt phosphorylation, whereas PTEN knockdown increased the levels of phosphorylated Akt (Fig. 4a). SHIP2 knockdown increased phosphorylated PAX, which was not increased by PTEN knockdown (Fig. 4a, PTEN silencing induced aberrant membrane ruffle formation and decreased cell area (Fig. 4b–d). Interestingly, the combination with SHIP2 knockdown suppressed these phenotypes (Fig. 4b–d). Compared to that in control cells, the fluorescence intensity of EGFP-TAPP1 PH was decreased by 60% in SHIP2-depleted cells, increased by 10% in PTEN-depleted cells, and decreased by 50% upon combined depletion of SHIP2 and PTEN (Fig. 4e). Fluorescence intensity of the EGFP-PLCγ1 PH was increased by 20% in SHIP2-depleted cells, and was not changed in PTEN-
**Discussion**

Alteration of PI3KCA, PTEN, PI(3,4)P2, and INPP4B is a common event in breast cancer,
(6,51) suggesting the importance of phosphoinositides in tumorigenesis. In this study, we revealed that PI(3,4)P2, rather than PI(3,4)P3, is important for lamellipodia formation in human cancer cells, which leads to cell motility and invasion. In basal-breast cancer cell lines, and specifically MDA-MB-231 cells, which lack INPP4B, intracellular PI(3,4)P2 and PI(3,4)P3 amounts are under the control of PTEN and PI(3,4)P3 phosphatases including SHIP2. SHIP2 expression is elevated in breast cancer cells promoting cell motility and invasion. In MDA-MB-231 cells, where SHIP2 expression is high, PI(3,4)P2 levels are low, indicating that increased SHIP2 activity leads to decreased PI(3,4)P2 levels, which in turn inhibits lamellipodia formation and cell spreading. These findings suggest that SHIP2 expression levels can modulate cell motility and invasion in breast cancer cells.

**Conclusion**

In summary, our study demonstrates the importance of PI(3,4)P2 in lamellipodia formation and cell motility in breast cancer cells. High SHIP2 expression was found to inhibit PI(3,4)P2 levels, leading to decreased lamellipodia formation and reduced cell motility. These findings have implications for the development of targeted therapeutics against breast cancer.

---

*Fig. 4.* Effect of SHIP2 and PTEN silencing on focal adhesion-related signaling molecules and focal adhesion formation. (a) Phosphorylation of PAX, FAK, and Akt in MDA-MB-231 cells transfected with PTEN siRNA and/or SHIP2 siRNA. Lysates were subjected to western blotting with the indicated antibodies. (b) PTEN and/or SHIP2-silenced MDA-MB-231 cells were stained with an anti-vinculin antibody. Actin was visualized with Alexa Fluor 647-conjugated-phalloidin. Scale bar = 10 μm. The number of invading cells, shown in (a), was counted. Results represent the mean ± SD of five independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 (Student–Newman–Keuls multiple comparison tests), n.s.: not significant.

*Fig. 5.* Effect of SHIP2 and PTEN knockdown on cell invasion. (a) An invasion assay was performed using MDA-MB-231 cells. Cells transfected with PTEN siRNA and/or SHIP2 siRNA were seeded in Matrigel invasion chambers and allowed to invade the Matrigel for 22 h. Invading cells were fixed and stained with propidium iodide. Scale bar = 100 μm. (b) The number of invading cells, shown in (a), was counted. Results represent the mean ± SD of five independent experiments. *P < 0.05. (e) Quantification of the relative amounts of PI(4,5)P2 (f) and PI(4)P (g) at the PM in MDA-MB-231 cells transfected with PTEN siRNA and/or SHIP2 siRNA. For the detection of PI(4,5)P2 and PI(4)P, GFP-PLC51-PH or GFP-FAPP1 PH was expressed in these cells. Data represent the mean ± SD, n, no. analyzed cells pooled from six independent experiments. *P < 0.05 (Student–Newman–Keuls multiple comparison tests), n.s.: not significant.
containing LN229 cells. These results are not consistent because SHIP2 functions as an oncogene. However, it also functions as a tumor suppressor in different cancer cells, which might be explained by different functions of PIP3 and PI(3,4)P2 in cancer cells. Therefore, it was suggested that the effect of SHIP2 on cell migration is dependent on cell types and is affected by PTEN status. Here, we show that in MDA-MB-231 breast cancer cells, SHIP2-depletion increased focal adhesion formation and cell area regardless of PTEN expression levels (Figs 4b–d), suggesting that PI(3,4)P2 generated by SHIP2 acts on focal adhesion dynamics and cell invasion. Akt phosphorylation was not markedly increased by SHIP2 knockdown in contrast to PTEN knockdown, indicating that PIP3 levels were not significantly affected by SHIP2. In contrast, knockdown of PTEN enhanced Akt phosphorylation markedly with slight increases in cell adhesion formation and cell invasion. These results suggest that PTEN knockdown increases PIP3, and slightly increases PI(3,4)P2 levels, in these cells. Treatment of PI 3-kinase inhibitors decreased PIP3 and PI(3,4)P2 generation, which in turn resulted in an increased number of focal adhesions and cell area. Taken together, PIP3 and PI(3,4)P2 have distinct roles in basal breast cancer phenotypes (Fig. 8). In MDA-MB-231 cells, which have high PTEN expression,52 PTEN predominantly regulates PIP3 levels, and is related to PI3-kinase signaling. In contrast, SHIP2 plays a role in the generation of PI(3,4)P2, which in turn leads to Lpd

Fig. 6. Lpd knockdown results in focal adhesion formation. (a) Phosphorylation of PAX, FAK, and Akt in MDA-MB-231 cells transfected with control-(CTL) or Lpd-targeted siRNA. Lysates were subjected to western blot analyses with the indicated antibodies. Results are presented as the mean ± SD of three independent experiments. *P < 0.01, n.s.: not significant. (b) MDA-MB-231 cells transfected with control-(CTL) or Lpd-targeted siRNA were stained with anti-VCL and anti-ZYX antibodies. Actin was visualized by Alexa Fluor 647-conjugated phalloidin. Scale bar = 10 μm. (c,d) Quantification of focal adhesion number per cell (c) and measurement of cell area (d) from cells shown in (a). Data represent the mean ± SD of 35 cells for the control, siLpd #1, and siLpd #2, respectively. *P < 0.01. (e) An invasion assay was performed using MDA-MB-231 cells. Cells transfected with siLpd #1 or siLpd #2 were seeded in Matrigel invasion chambers and allowed to invade the Matrigel for 22 h. Invading cells were fixed and stained with propidium iodide. Scale bar = 100 μm. (f) The number of invading cells, shown in (e), was counted. Results represent the mean ± SD of three independent experiments. *P < 0.01.
signaling and lamellipodia formation. The control effect of SHIP2 on cell migration varies widely in different cell types. Although the reason for the differences between cells is not understood, differences in the status of other phosphoinositide phosphatases including INPP4B can affect the amounts of phosphoinositides including PIP3, PI(3,4)P2, and PI(4,5)P2 and determine the function of SHIP2 in invasive phenotypes of cancer cells.

Among these phosphoinositides, PI(4,5)P2 increases FAK phosphorylation and facilitates directional cell migration through interaction with its effector IQ Motif Containing GTPase Activating Protein 1 (IQGAP1). (53) In 1321 N1 glioblastoma cells, SHIP2 depletion increased PI(4,5)P2 levels by two-fold and facilitated FAK phosphorylation. In MDA-MB-231 cells, SHIP2 depletion increased the amount of PI(4,5)P2 by only 20%; and we could not detect an increase in FAK phosphorylation. These results suggest that SHIP2 does not affect PI(4,5)P2-dependent regulation of cell migration and invasion in MDA-MB-231 cells. Lpd was shown to be required for metastasis in an orthotopic breast cancer mouse model, and increased Lpd expression suppressed metastasis-free survival in breast cancer patients. (51) These data suggest that the inhibition of Lpd-Rac-WAVE pathway causes a shift from membrane ruffling and lamellipodia formation to focal adhesion development. Although underlying mechanisms of how PI(3,4)P2 and its downstream effectors mediate PAX phosphorylation remain to be solved, increase in PAX phosphorylation by SHIP2 and Lpd knockdown is likely to induce development of
focal adhesion and enlargement of breast cancer cell. Thus, it is possible that SHIP2 enhances the formation of PI(3,4,5)P2, which in turn activates Lpd, leading to increased cell invasion and metastasis.

Author contribution
M. F and T. I. performed the experiments and analyzed the data. T. I and T. T designed the study and wrote the paper. All authors discussed the results and commented on the manuscript.

References

1. Krause M, Gautreau A. Steering cell migration: lamellipodium dynamics and the regulation of directional persistence. Nat Rev Mol Cell Biol 2014; 15: 577–90.
2. Bae YH, Ding Z, Das T, Wells A, Gertler F, Roy P. Profilin1 regulates PI(3,4,5)P2 and lamellipodium accumulation at the leading edge thus influencing motility of MDA-MB-231 cells. Proc Natl Acad Sci USA 2010; 107: 21547–52.
3. Law AL, Vehlow a, Kotini M et al. Lamellipodin and the Scar/WAVE complex cooperate to promote cell migration in vivo. J Cell Biol 2013; 203: 673–89.
4. Lopez-Knowles E, O’Toole SA, McNeil CM et al. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 2010; 126: 1121–31.
5. Ma CX, Ellis MJ. The Cancer Genome Atlas: clinical applications for breast cancer. Oncology (Williston Park) 2013; 27(1263–9): 74–9.
6. Pang B, Cheng S, Sun SP et al. Prognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer: a meta-analysis. Sci Rep 2014; 4: 6255.
7. Cuorvo LV, Verderio P, Ciniselli CM et al. PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy. Virchows Arch 2014; 464: 85–93.
8. Gonzalez-Angulo AM, Chen H, Karuturi MS et al. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer 2013; 119: 7–15.
9. Stambolic V, Suzuki A, de la Pompa JL et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Oncogene 2015; 34: 3711–27.
10. Ooms LM, Bings LC, Davies EM et al. The Inositol Polyphosphate 5-Phosphatase PIP5P Regulates AKT1-dependent breast cancer growth and metastasis. Cancer Cell 2015; 28: 155–69.
11.Giuriato S, Blero D, Robaye B, Bruyns C, Payraste B, Erneux C. SHIP2 overexpression strongly reduces the proliferation rate of K562 erythroleukaemia cell line. Biochem Biophys Res Commun 2002; 296: 106–10.
12. Taylor V, Wong M, Brandsd C et al. 5’ phospholipid phosphatase SH2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells. Mol Cell Biol 2000; 20: 6860–71.
13. Clement S, Krause U, Desmedt F et al. The lipid phosphatase SHIP2 controls insulin sensitivity. Nature 2001; 409: 92–7.
14. Prasad N, Topping RS, Decker SJ. Src family tyrosine kinases regulate adhesion-dependent tyrosine phosphorylation of 5’-inositol phosphatase SH2 during cell attachment and spreading on collagen I. J Cell Sci 2002; 115: 3807–15.
15. Takabayashi T, Xie MJ, Takeuchi S et al. LLBeta directs the translocalization of filamin A and SHIP2 to sites of phosphatidylinositol 3,4,5-triphosphate (PtdIns(3,4,5)P3) accumulation, and PtdIns(3,4,5)P3 localization is mutually modified by co-recruited SHIP2. J Biol Chem 2010; 285: 16155–65.
16. Edmo WE, Ramos AR, Ghosh S, Vanderwinden JM, Erneux C. The SHIP2 interactor Myo6 is required for cell migration in 1321 N1 glioblastoma cells. Biochem Biophys Res Commun. 2016; 476: 508–14.
17. Edmo WE, Ghosh S, Derra R et al. SHIP2 controls plasma membrane PI (4,5)P2 thereby participating in the control of cell migration in 1321 N1 glioblastoma. J Cell Sci 2016; 129: 1101–14.
18. Fu M, Fan W, Xu X et al. Elevated expression of SHIP2 correlates with poor prognosis in non-small cell lung cancer. Int J Clin Exp Pathol 2013; 6: 2185–91.
19. Yang J, Fu M, Ding Y et al. High SHIP2 expression indicates poor survival in colorectal cancer. Dis Markers 2014; 2014: 218968.
20. Hasegawa J, Tokuda E, Tenno T et al. SH3YL1 regulates dorsal ruffle formation by a novel phosphoinositide-binding domain. J Cell Biol 2011; 193: 901–12.
21. Sharma VP, Eddy R, Entenberg D, Kai M, Gertler FB, Condeelis J. Tks5 and SHIP2 regulate invadopodium maturation, but not initiation, in breast carcinoma cells. Carc Res 2013; 23: 2079–89.
22. Li H, Wu X, Hou S et al. Phosphatidylinositol-3,4-bisphosphate and its binding protein lamellipodin regulate chemotaxis of malignant B lymphocytes. J Immunol 2016; 196: 886–95.
23. Hawkins PT, Stephens LR. Emerging evidence of signalling roles for PI(3,4)P2 in Class I and II PI3K-regulated pathways. Biochem Soc Trans 2016; 44: 307–14.
24. Chen XJ, Squarr AJ, Stephen R et al. Ena/VASP proteins cooperate with the WAVE complex to regulate the actin cytoskeleton. Dev Cell 2014; 30: 569–84.
25. Hansen SD, Mullins RD. Lamellipodin promotes actin assembly by clustering Ena/VASP proteins and tethering them to actin filaments. eLife. 2015; 4: e07554.
26. Chen CS, Alonso JL, Ostuni E, Whitesides GM, Ingber DE. Cell shape provides global control of focal adhesion assembly. Biochem Biophys Res Commun 2003; 307: 355–61.

Acknowledgments
We are grateful to Shunichi Nakamura (Kobe University Graduate School of Medicine) for their assistance. This work was supported by grants to T. I. from the Japan Society for the Promotion of Science (JSPS; Kakenhi grant number 16K08585). The Funding agency had no role in the study design, data collection and analysis, decision to publish, or presentation of the manuscript.

Disclosure
The authors have no conflict of interest.
41 Kanchanawong P, Shtengel G, Pasapera AM et al. Nanoscale architecture of integrin-based cell adhesions. *Nature* 2010; 468: 580–4.
42 Bae YH, Mui KL, Hsu BY et al. A FAK-Cas-Rac-lamellipodin signaling module transduces extracellular matrix stiffness into mechanosensitive cell cycling. *Science Signaling* 2014; 7: ra57.
43 Yamashita H, Ichikawa T, Matsuyama D et al. The role of the interaction of the vinculin proline-rich linker region with vinexin alpha in sensing the stiffness of the extracellular matrix. *J Cell Sci* 2014; 127: 1875–86.
44 Furutani M, Itoh T, Ijuin T, Takenawa T. Thin layer chromatography-blotting, a novel method for the detection of phosphoinositides. *J Biol Chem* 2006; 281: 663–70.
45 Basson MD. An intracellular signal pathway that regulates cancer cell adhesion in response to extracellular forces. *Cancer Res* 2008; 68: 2–4.
46 Calderwood DA, Shattil SJ, Ginsberg MH. Integrins and actin filaments: reciprocal regulation of cell adhesion and signaling. *J Biol Chem* 2000; 275: 22607–10.
47 Parsons JT, Martin KH, Slack JK, Taylor JM, Weed SA. Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. *Oncogene* 2000; 19: 5606–13.
48 Burridge K, Turner CE, Romer LH. Tyrosine phosphorylation of paxillin and pp125FAK accompanies cell adhesion to extracellular matrix: a role in cytoskeletal assembly. *J Cell Biol* 1992; 119: 893–903.
49 Wang SY, Basson MD. Akt directly regulates focal adhesion kinase through association and serine phosphorylation: implication for pressure-induced colon cancer metastasis. *Am J Physiol-Cell Ph* 2011; 300: C657–70.
50 Dowler S, Currie RA, Campbell DG et al. Identification of pleckstrin-homology-domain-containing proteins with novel phosphoinositide-binding specificities. *Biochem J* 2000; 351: 19–31.
51 Carmona G, Perera U, Gillett C et al. Lamellipodin promotes invasive 3D cancer cell migration via regulated interactions with Ena/VASP and SCAR/WAVE. *Oncogene* 2016; 35: 5155–69.
52 Sosa MS, Lopez-Haber C, Yang C et al. Identification of the Rac-GEF P-Rex1 as an essential mediator of ErbB signaling in breast cancer. *Mol Cell* 2010; 40: 877–92.
53 Choi S, Thapa N, Hedman AC, Li Z, Sacks DB, Anderson RA. IQGAP1 is a novel phosphatidylinositol 4,5 bisphosphate effector in regulation of directional cell migration. *EMBO J* 2013; 32: 2617–30.